Background/Aims Identifying patients with intrahepatic cholangiocarcinoma (ICC) likely to benefit from immunochemotherapy, the new front-line treatment, remains challenging. We aimed to unveil a novel radiotranscriptomic signature that can facilitate treatment response prediction by multi-omics integration and multiscale modelling.
Methods We analyzed bulk, single-cell and spatial transcriptomic data comprising 457 ICC patients to identify an immune-related score (IRS), followed by decoding its spatial immune context. We mapped radiomics profiles onto spatial-specific IRS using machine learning to define a novel radiotranscriptomic signature, followed by multi-scale and multi-cohort validation covering 331 ICC patients. The signature was further explored for the potential therapeutic target from in vitro to in vivo.
Results We revealed a novel 3-gene (PLAUR, CD40LG, and FGFR4) IRS whose down-regulation correlated with better survival and improved sensitivity to immunochemotherapy. We highlighted functional IRS-immune interactions within tumor epithelium, rather than stromal compartment, irrespective of geospatial locations. Machine learning pipeline identified the optimal 3-feature radiotranscriptomic signature that was well-validated by immunohistochemical assays in molecular cohort, exhibited favorable external prognostic validity with C-index over 0.64 in resection cohort, and predicted treatment response with an area under the curve of up to 0.84 in immunochemotherapy cohort. We also showed that anti-uPAR/PLAUR alone or in combination with anti-programmed cell death protein 1 therapy remarkably curbed tumor growth, using in vitro ICC cell lines and in vivo humanized ICC patient-derived xenograft mouse models.
Conclusions This proof-of-concept study sheds light on the spatially-resolved radiotranscriptomic signature to improve patient selection for emerging immunochemotherapy and high-order immunotherapy combinations in ICC.
Citations
Citations to this article as recorded by
Immunotherapy impact of macrophage glycosylation on cholangiocarcinoma and its prognostic and immune microenvironment significance Yufen Xu, Xiaofang Xu, Yan Xu, Jianwen Duan Human Vaccines & Immunotherapeutics.2026;[Epub] CrossRef
Bioinformatics analysis of PLAUR and its oncogenic role of promoting colorectal cancer progression through the AKT/p53 signaling You Chen, Rui Ma, Chuyue Wang, Zhiying Yang, Ying Shi, Yingying Zhao, Xiaofen Pan, Bo Wang, Weili Wu, Ping Yuan Experimental Cell Research.2026; 455(2): 114850. CrossRef
Letter to the editor on “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target” Yuqian Liu, Ruiyun Guo, Jun Ma Clinical and Molecular Hepatology.2026; 32(1): e13. CrossRef
How to efficiently establish animal models of cholangiocarcinoma: challenges and inspiration Ruiqiang Gou, Ping Yue, Peng Liu, Jinyu Zhao, Chunfei Huang, Kiyohito Tanaka, Peng F Wong, Rungsun Rerknimitr, Jong H Moon, Tan T Cheung, Christian Waydhas, Azumi Suzuki, Yanyan Lin, Emmanuel Melloul, Hans Schlitt, John Fung, Joseph W Leung, Wenbo Meng Medical Review.2026; 6(2): 91. CrossRef
Integrating single-cell atlases and machine learning to construct ‘in silico patients’ for predicting individualized drug responses Zhuo Zuo, Yulong Sun Biochemical Pharmacology.2026; 248: 117873. CrossRef
AI-Driven Drug Discovery: Focus on Targets for Solid Tumors Jialong Wu, Jide He, Qianyang Ni, Zi’ang Li, Xiushi Lin, Zhenkun Zhao, Lei Qiu, Hongyin Wang, Sijie Li, Chengdong Shi, Yunyi Zhang, Huile Gao, Jian Lu Pharmaceutics.2026; 18(3): 329. CrossRef
Multifacet Roles of Cellular Senescence in Cancer: Mechanisms and Therapeutic Implications Huajie Mao, Wanning Liu, Yuanyuan Su, Yuxuan Ma, Xiaodi Zhao, Yuanyuan Lu MedComm – Oncology.2026;[Epub] CrossRef
Biliary tract cancer treatment: Emerging trends and further prospects Qinqin Liu, Honghua Zhang, Li Pang, Xinjian Xu, Chao Liu Chinese Medical Journal BioMed.2026;[Epub] CrossRef
Advances in In Vitro Diagnostics for Cholangiocarcinoma: From Biomarker Discovery to Artificial Intelligence Chengrui Mo, Xinping Hu, Zhu Yuan, Tiancai Liu International Journal of Molecular Sciences.2026; 27(9): 3779. CrossRef
Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025 Qi-Feng Chen, Yue Hu, Song Chen, Xiong-Ying Jiang, Ming Zhao Liver Cancer.2026; : 1. CrossRef
The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer Emanuelle Rizk, Patrick Foley, Soravis Osataphan Cancers.2026; 18(12): 2001. CrossRef
Advances in the Molecular Mechanisms of Cholangiocarcinoma: A Comprehensive Review of Biomarkers, Regulatory Pathways and Tumor Microenvironment Reprogramming Yange Wang, Yanhua Yang, Meijing Wang, Zhonghua Liu, Meina Wang, Lu Zhang, Xiangqian Guo International Journal of Molecular Sciences.2026; 27(14): 6362. CrossRef
Comparison of current global guidelines and consensus on the management of patients with cholangiocarcinoma: A 2026 update Enyang He, Yulong Cai, Xianze Xiong, Rongxing Zhou, Fuyu Li, Nansheng Cheng BioScience Trends.2026;[Epub] CrossRef
192Ir brachytherapy combined with external beam radiotherapy and biliary stenting for unresectable hilar cholangiocarcinoma Wenbo Yang, Yinghao Wang, Li Xiao, Fei Liu, Jianxi Zhou, Yunchuan Sun Frontiers in Oncology.2026;[Epub] CrossRef
Digital and Biological Twins in Cholangiocarcinoma: From Translational Research to Precision Medicine—A Narrative Review Lorenzo Manganaro, Giuseppe De Sario, Guido Carpino, Lewis J. Frey, Eugenio Gaudio, Wing-Kin Syn, Domenico Alvaro, Vincenzo Cardinale Livers.2026; 6(4): 80. CrossRef
Application of intratumoral and peritumoral radiomics based on multimodal MRI in predicting the pathological grade of intrahepatic mass-forming cholangiocarcinoma Erhao Zheng, Jiawei Tian, Lun Zhang, Dan An, Jigang Bai Journal of Radiation Research and Applied Sciences.2026; 19(3): 102592. CrossRef
Machine Learning–Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma Jun-Hao Mei, Kai Zhang, Ying Zhang, Zhen Li, Nai-Jian Ge, Xue Han, Sui-Xing Zhong, Xiu-Ping Zhang, Ping-Ping Wu, Wei-Fu Lv, Jun Wu, Jian-Xiong Wu, Chao Wang, Hui Yan, Tian Huang, Jie Liu, Kai-Zhi Jia, Yue Liu, Jin-He Guo, Rong Liu, Gao-Jun Teng, Jian Lu JHEP Reports.2026; : 102004. CrossRef
Characterization of hypoxia-related molecular clusters and prognostic riskScore for glioma Xiang Fang, Xinhao Wu, Chengran Xu Frontiers in Oncology.2025;[Epub] CrossRef
Artificial intelligence in the diagnosis and prognosis of intrahepatic cholangiocarcinoma: Applications and challenges Liang Qiao, Yu-Gang Luo, Qing-Ying Wang, Tian Yuan, Meng Xu, Guang-Bing Xiong, Feng Zhu World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
First
Prev
